Puxitatug samrotecan
Based on 1 Customer Validation
Puxitatug samrotecan (AZD 8205) is an antibody-drug conjugate (ADC) targeting B7-H4, formed by the random conjugation of the Puxitatug (HY-P990059) antibody and AZ14170133 (HY-145399) via interchain cysteine reduction. Puxitatug samrotecan binds to B7-H4 to deliver the payload to B7-H4-expressing cells, inhibits topoisomerase I, and induces cytotoxicity in cancer cells and xenograft models. Puxitatug samrotecan can be used in studies of B7-H4-expressing tumors.
For research use only. We do not sell to patients.
- Purity: 98.51%
- CAS No.: 2760250-80-2
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Topoisomerase Isoforms
More
Biological Activity
|
Topoisomerase I |
Puxitatug samrotecan (AZD 8205) exhibits improved biophysical stability relative to alternative linker-payload ADC configurations tested[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:patient-derived xenograft model[1]
-
Dosage:3.5 mg/kg
-
Administration:single administration
-
Result:Achieved a 69% overall response rate, as defined by modified RECIST criteria.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2760250-80-2
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Puxitatug samrotecan]
-
Synonyms
AZD 8205; P-Sam
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kinneer K, et al. Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Mar 14;29(6):1086-1101. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Puxitatug samrotecan Related Classifications
HY-171689 Related Classifications
Powered by Bioz
- Puxitatug samrotecan
- 2760250-80-2
- AZD 8205
- P-Sam
- AZD8205
- AZD-8205
- Antibody-Drug Conjugates (ADCs)
- Topoisomerase
- CD276/B7-H3
- homologous recombination repair deficiency
- cancer cells
- ovarian cancer
- B7-H4
- cholangiocarcinoma
- B7-H4-expressing tumors
- xenograft models
- topoisomerase I
- HR+/HER2- breast cancer
- endometrial cancer
- Inhibitor
- inhibitor
- inhibit